Recent News

Print
and/or
28 News Items found

Announcement

FDA Approves Enasidenib (Idhifa), a First-of-Its-Kind Drug, for Advanced Blood Cancer

A new treatment option for people with acute myeloid leukemia is available, and it works in an unconventional way.

Acute myeloid leukemia cells under a microscope

In the Lab

Giving Drugs Together — Rather than in Sequence — May Be Key to Halting Tumor Resistance

Scientists are learning how tumors develop resistance to drugs — and what can be done about it.

Representative image of a dividing tumor cell showing the extrachromosomal location of duplicated BRAF genes

In the News

#ASCO17: Post-Conference Roundup of Themes and Trends

Read up on the progress being made in several key areas of cancer research, including immunotherapy, targeted therapy, precision surgery, and epigenetics.

American Society of Clinical Oncology logo

Feature

With MSK Leading the Way, Precision Medicine Links Lab Research to Patient Care

Therapies that target genetic alterations in tumors are showing promise for many cancer patients, but challenges in developing these new treatments remain.

Decoder

What Are Exceptional Responders?

When a clinical trial of a new drug fails because most patients don’t respond, progress can still be made by analyzing the tumors of the rare patients who benefit.

Exceptional responders of new drugs in clinical trials.

In the Clinic

The Evolution of a Lifesaving Drug: A Scientist Reflects

Physician-scientist Charles Sawyers played a pivotal role in the development of Gleevec, one of the first successful targeted drugs for cancer.

Pictured: Charles Sawyers

In the Clinic

Report Highlights Advances Made at MSK That Are Changing Patients’ Lives

An annual report from an influential cancer group highlights three MSK studies that have advanced cancer research.

New treatments developed at MSK focus on both common and rare cancers.

Finding

Study Reveals How Some Breast Cancers Become Resistant to Targeted Drugs

A study of one patient’s disease has clarified why tumors stop responding to a class of experimental drugs called PI3K inhibitors.

MSK investigators Michael Berger and David Solit.

Decoder

What Is Epigenetics?

Physician-scientist Omar Abdel-Wahab explains epigenetics, a growing field based on the study of genetic changes that are not part of the DNA code, and how it relates to cancer.

DNA wrapped around histones